Abstract
Background Patients with metastatic renal cell carcinoma (mRCC) with renal insufficiency are generally excluded from clinical trials, despite their increasing numbers. Thus, we evaluated the efficacy and toxicity of sunitinib in such patients. Patients and methods Korean patients with mRCC with renal insufficiency who had received sunitinib as first-line treatment between January 2008 and May 2012 were included. Patient characteristics, clinical outcomes and toxicities were evaluated. Overall survival (OS) and progression-free survival (PFS) were determined according to the degree of renal impairment. Results The median age of the 34 patients evaluated was 66 years, 90% had an Eastern Cooperative Oncology Group performance status of 0 or 1 and the median glomerular filtration rate was 46.5 mL min -1 ·1.73 m -2 (range, 21.1-59.5). The starting sunitinib dose was 37.5 and 50 mg for 12 and 22 patients, respectively. A 4-weeks-on-2-weeks-off regimen was followed for 31 patients; a 2-weeks-on-2-weeks-off regimen, for one patient; and a daily regimen, for two patients. The best response was partial response in eight patients and stable disease in 12. Median OS and PFS times were 26.3 months (95% confidence interval [CI]: 17.1-35.3) and 12.2 months (95% CI: 10.2-13.2), respectively. Common non-haematologic adverse events (AEs) were stomatitis, rash, general oedema and fatigue. The most common AEs of ≥grade 3 severity were fatigue, neutropenia and thrombocytopenia. Conclusions In patients with mRCC with renal insufficiency, sunitinib was efficacious and did not cause increased toxicity. Thus, clinicians should not hesitate to treat patients with mRCC with renal insufficiency with sunitinib.
| Original language | English |
|---|---|
| Pages (from-to) | 746-752 |
| Number of pages | 7 |
| Journal | European Journal of Cancer |
| Volume | 50 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2014 Mar 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Cite this
}
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency. / Kim, Ki Hyang; Kim, Ho Young; Kim, Hye Ryun; Sun, Jong Mu; Lim, Ho Yeong; Lee, Hyo Jin; Lee, Suee; Bae, Woo Kyun; Rha, SunYoung.
In: European Journal of Cancer, Vol. 50, No. 4, 01.03.2014, p. 746-752.Research output: Contribution to journal › Article
TY - JOUR
T1 - Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency
AU - Kim, Ki Hyang
AU - Kim, Ho Young
AU - Kim, Hye Ryun
AU - Sun, Jong Mu
AU - Lim, Ho Yeong
AU - Lee, Hyo Jin
AU - Lee, Suee
AU - Bae, Woo Kyun
AU - Rha, SunYoung
PY - 2014/3/1
Y1 - 2014/3/1
N2 - Background Patients with metastatic renal cell carcinoma (mRCC) with renal insufficiency are generally excluded from clinical trials, despite their increasing numbers. Thus, we evaluated the efficacy and toxicity of sunitinib in such patients. Patients and methods Korean patients with mRCC with renal insufficiency who had received sunitinib as first-line treatment between January 2008 and May 2012 were included. Patient characteristics, clinical outcomes and toxicities were evaluated. Overall survival (OS) and progression-free survival (PFS) were determined according to the degree of renal impairment. Results The median age of the 34 patients evaluated was 66 years, 90% had an Eastern Cooperative Oncology Group performance status of 0 or 1 and the median glomerular filtration rate was 46.5 mL min -1 ·1.73 m -2 (range, 21.1-59.5). The starting sunitinib dose was 37.5 and 50 mg for 12 and 22 patients, respectively. A 4-weeks-on-2-weeks-off regimen was followed for 31 patients; a 2-weeks-on-2-weeks-off regimen, for one patient; and a daily regimen, for two patients. The best response was partial response in eight patients and stable disease in 12. Median OS and PFS times were 26.3 months (95% confidence interval [CI]: 17.1-35.3) and 12.2 months (95% CI: 10.2-13.2), respectively. Common non-haematologic adverse events (AEs) were stomatitis, rash, general oedema and fatigue. The most common AEs of ≥grade 3 severity were fatigue, neutropenia and thrombocytopenia. Conclusions In patients with mRCC with renal insufficiency, sunitinib was efficacious and did not cause increased toxicity. Thus, clinicians should not hesitate to treat patients with mRCC with renal insufficiency with sunitinib.
AB - Background Patients with metastatic renal cell carcinoma (mRCC) with renal insufficiency are generally excluded from clinical trials, despite their increasing numbers. Thus, we evaluated the efficacy and toxicity of sunitinib in such patients. Patients and methods Korean patients with mRCC with renal insufficiency who had received sunitinib as first-line treatment between January 2008 and May 2012 were included. Patient characteristics, clinical outcomes and toxicities were evaluated. Overall survival (OS) and progression-free survival (PFS) were determined according to the degree of renal impairment. Results The median age of the 34 patients evaluated was 66 years, 90% had an Eastern Cooperative Oncology Group performance status of 0 or 1 and the median glomerular filtration rate was 46.5 mL min -1 ·1.73 m -2 (range, 21.1-59.5). The starting sunitinib dose was 37.5 and 50 mg for 12 and 22 patients, respectively. A 4-weeks-on-2-weeks-off regimen was followed for 31 patients; a 2-weeks-on-2-weeks-off regimen, for one patient; and a daily regimen, for two patients. The best response was partial response in eight patients and stable disease in 12. Median OS and PFS times were 26.3 months (95% confidence interval [CI]: 17.1-35.3) and 12.2 months (95% CI: 10.2-13.2), respectively. Common non-haematologic adverse events (AEs) were stomatitis, rash, general oedema and fatigue. The most common AEs of ≥grade 3 severity were fatigue, neutropenia and thrombocytopenia. Conclusions In patients with mRCC with renal insufficiency, sunitinib was efficacious and did not cause increased toxicity. Thus, clinicians should not hesitate to treat patients with mRCC with renal insufficiency with sunitinib.
UR - http://www.scopus.com/inward/record.url?scp=84894099511&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84894099511&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2013.11.029
DO - 10.1016/j.ejca.2013.11.029
M3 - Article
VL - 50
SP - 746
EP - 752
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 4
ER -